oral semaglutide alternative
The Drug That Could Make GLP-1 Injections Optional Just Hit a Key Milestone
The GLP-1 drug market is already worth over $50 billion annually. Every major player in it requires an injection. That is the gap ASC30 is targeting. Ascletis Pharma (HKEX: 1672) announced on April 26, 2026 that it has completed enrollment in its 13-week US Phase II study of ASC30, an oral small molecule GLP-1 receptor…
